Company news

Seres Therapeutics, Inc. (NASDAQ:MCRB) news

Seres Therapeutics, Inc. news releases on 6ix. Latest, Sep 1, 2026: Seres Therapeutics to Participate in H.C. Wainwright 28th Annual Global Investment…

Seres Therapeutics, Inc. (NASDAQ:MCRB) news

Press releases & updates

Seres Therapeutics to Participate in H.C. Wainwright 28th Annual Global Investment Conference

Seres Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Updates, Including Further Action to Reduce Ongoing Facilities Costs

Seres Therapeutics Announces Early Clinical Data Showing Potential for SER-155 in Immune Checkpoint Inhibitor-Related Enterocolitis (irEC), a Frequent Adverse Reaction That Forces Many Patients to Halt Cancer Treatment

Seres Therapeutics Announces Two Transactions to Strengthen Balance Sheet, Reduce On-Going Lease Costs and Extend Projected Operating Cash Runway Well Into the First Quarter of 2027

Seres Therapeutics to Participate in H.C. Wainwright 4th Annual BioConnect Investor Conference

Seres Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Updates

Seres Therapeutics Presents Preclinical Data at Digestive Disease Week (DDW) 2026 Supporting SER-603, a Next-Generation Cultivated Live Biotherapeutic Candidate, for Inflammatory Bowel Disease

Seres Therapeutics Showcases SER-155 Data and Live Biotherapeutic Insights at ESCMID Global 2026

Seres Therapeutics to Present at CARB-X Investor Day

Seres Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates

Seres Therapeutics Announces Appointment of Richard N. Kender as Executive Chair and Interim CEO; Provides Business Updates

Seres Provides Program and Corporate Updates and Prioritizes Emerging Programs in Inflammatory & Immune Diseases

Particles for Humanity Appoints Marcus Chapman as Senior Vice President and Head of Finance

Seres Therapeutics Announces Publications in Nature Medicine and Journal of Infectious Diseases Highlighting Vowst™ Mechanism of Action and Supporting Broader Live Biotherapeutic Strategy

Seres Therapeutics to Participate in Piper Sandler Healthcare Conference

Seres Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Updates

Seres Therapeutics to Announce Third Quarter 2025 Financial Results and Business Updates on November 5, 2025

Seres Therapeutics Receives Award of Up to $3.6 Million from CARB-X to Develop Liquid Formulation of SER-155

Seres Therapeutics to Present New Post Hoc Data From SER-155 Phase 1b Trial at IDWeek 2025, Highlighting Potential to Improve Outcomes in Adults Undergoing Allogeneic Hematopoietic Stem Cell Transplant

Seres Therapeutics Announces Further Constructive Feedback from FDA on SER-155 Phase 2 Study Protocol and Implements Cost Reduction Actions to Extend Cash Runway

Seres Therapeutics to Participate in H.C. Wainwright 27th Annual Global Investment Conference

Seres Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Updates

Seres Therapeutics to Announce Second Quarter 2025 Financial Results and Business Updates on August 6, 2025

Seres Therapeutics Announces Leadership Transition

Seres Therapeutics Presents Expanded SER-155 Exploratory Biomarker Data at 2025 ASCO Annual Meeting

Seres Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Updates

Seres Therapeutics Presents Data at the 2025 Digestive Disease Week Conference Highlighting the Potential for Live Biotherapeutics to Treat Inflammatory and Immune Diseases

Seres Therapeutics to Announce First Quarter 2025 Financial Results and Business Updates on May 7, 2025

Seres Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates

Seres Therapeutics to Announce Fourth Quarter and Full Year 2024 Financial Results and Provide Business Updates on March 13, 2025

Seres Therapeutics Receives Feedback From FDA on SER-155 Allogeneic Hematopoietic Stem Cell Transplant (allo-HSCT) Development Approach

Seres Therapeutics Announces Receipt of Expected $50 Million Installment Payment Related to VOWST Sale

Seres Therapeutics Announces New Translational Biomarker Results from SER-155 Phase 1b Clinical Study and Provides Corporate Updates

FDA Grants Breakthrough Therapy Designation to Seres Therapeutics’ SER-155 for Reduction of Bloodstream Infections in Adults Undergoing Allogeneic Hematopoietic Stem Cell Transplant (allo-HSCT)

Seres Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Updates

Seres Therapeutics Announces Completion of VOWST™ Asset Sale to Société des Produits Nestlé S.A

Seres Therapeutics Stockholders Approve Sale of VOWST™ to Nestlé Health Science; Sale Expected to Close on September 30

Seres Therapeutics Reports SER-155 Phase 1b Placebo-Controlled Cohort 2 Study Safety and Clinical Results in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplant (allo-HSCT)

Seres Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Updates

Seres Therapeutics Announces Signing of VOWST™ Asset Purchase Agreement with Nestlé Health Science

Seres Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Seres Therapeutics Enters Into Memorandum of Understanding For Vowst™ Asset Sale to Nestlé Health Science

Seres Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Updates

Seres Therapeutics to Announce First Quarter 2024 Financial Results and Business Update on May 8, 2024

Seres Therapeutics Announces Completion of Patient Enrollment for SER-155 Phase 1B Cohort 2 Clinical Trial in Allogenic HSCT

Seres Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Updates

Seres Therapeutics Announces the Appointment of Marella Thorell as Chief Financial Officer and the Retirement of David Arkowitz

Seres Therapeutics Announces VOWST™ Commercial Launch Update and US FDA Fast Track Designation for SER-155

Seres Therapeutics Announces Presentation of Preliminary PK/PD and Safety Data for Investigational Microbiome Therapeutic SER-155 at ASH 2023

Seres Therapeutics Reports Third Quarter 2023 Financial Results Including VOWST™ Net Sales of $7.6 Million